By Paul Ziobro
Ascendis Pharma said the Food & Drug Administration will review an application to expand the use of its drug to treat growth hormone deficiency to adults.
The Danish biopharma company on Thursday said the FDA accepted its supplemental biologics application in adult growth hormone deficiency for TransCon hGH, which is marketed as Skytrofa for pediatric patients.
"This marks another step towards achieving our objective to expand Skytrofa's label beyond pediatric GHD and expand its reach to address new groups of patients," Ascendis Chief Executive Jan Mikkelsen said.
The application is based on results from a trial that compared the efficacy and safety of weekly TransCon hGH with a weekly placebo and daily human growth hormone in adults with growth hormone deficiency.
Write to Paul Ziobro at paul.ziobro@wsj.com
(END) Dow Jones Newswires
December 12, 2024 17:21 ET (22:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。